SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Cablivi

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already on the market. First approved in the US in February 2019 and in the EU in September 2018.
Why 3/10
Cablivi is an already-approved, commercialized drug with no pending regulatory decision or pivotal readout in the next 12 months. The pediatric label expansion (the most recent binary catalyst) already occurred in December 2025/January 2026. Per the rubric, an approved drug with no imminent new regulatory decision scores 3-5, and Cablivi is a modest contributor (roughly EUR 249M in 2024 sales) within Sanofi's massive EUR 51B+ revenue base, further anchoring the score at the low end of that range.
Actionable Insight NEUTRAL

Cablivi has no scheduled PDUFA dates, AdComms, or pivotal readouts in the next 12 months. The key binary event (pediatric label expansion) already passed in early 2026. Watch Sanofi's Q4 2026 earnings (late January 2027) for Cablivi's quarterly sales trajectory and any commentary on competitive dynamics from emerging aTTP therapies. The next major Sanofi rare-disease catalyst is the venglustat PDUFA for Gaucher disease type 3 on November 25, 2026, a separate drug.

Price Chart

Loading chart...

Executive Summary

Cablivi (caplacizumab-yhdp) is a first-in-class nanobody therapy for acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening blood clotting disorder. Originally FDA-approved in February 2019 for adults, Sanofi secured a pediatric label expansion in December 2025 (announced January 2026) covering patients 12 years and older. The drug generated approximately EUR 249 million in 2024 sales (about 9.7% growth), making it a modest but steadily growing contributor within Sanofi's much larger rare-disease portfolio. With no pending regulatory decisions or pivotal readouts, Cablivi is a mature, commercial-stage asset with limited near-term binary catalysts for the stock.

How It Works

Cablivi is a type of engineered antibody fragment (called a nanobody) that blocks von Willebrand factor, a protein in the blood that helps platelets stick together and form clots. In aTTP, abnormal clumps of von Willebrand factor cause dangerous small blood clots throughout the body. By blocking this protein, Cablivi helps prevent those clots from forming.

Trial Status

Cablivi was approved by the FDA on February 6, 2019 for adults with aTTP based on the pivotal Phase 3 HERCULES trial. The FDA expanded the label on December 23, 2025 (announced January 5, 2026) to include pediatric patients 12 years and older, supported by retrospective real-world data showing an 80% clinical remission rate in 30 children. The drug is also approved in the European Union (since September 2018). Additional real-world evidence continues to accumulate, including the Capla 1000+ project (Coppo et al. 2025).

The Two-Sided Case

▲ Bull Case4
Cablivi is the first and only FDA-approved therapy specifically for aTTP, giving it a strong niche position in a rare disease with high mortality if untreated.
Sales grew 9.7% in 2024 to EUR 249 million, with continued growth from increased diagnosis rates, expanded specialty hematology centers, and the new pediatric indication (12+).
The pediatric label expansion (December 2025) opens a new patient segment with no other approved targeted therapy, supporting continued revenue growth.
Sanofi's rare disease portfolio grew 12.6% in Q3 2026, and Cablivi benefits from Sanofi's commercial infrastructure and rare-disease expertise.
▼ Bear Case5
Cablivi is a tiny fraction (roughly 0.5%) of Sanofi's total revenue, so even strong sales growth has negligible impact on the stock.
The aTTP market is very small (ultra-rare disease), capping the drug's peak revenue potential well below blockbuster status.
Emerging competitors such as rilzabrutinib, ianalumab, and mezagitamab could eventually challenge Cablivi's position in the TTP treatment landscape.
The drug carries a bleeding risk (including life-threatening/fatal bleeding), especially with concomitant antiplatelet or anticoagulant use, which may limit adoption in certain patients.
Pricing and reimbursement pressures in the US (noted in Q4 2025 results where price impact partially offset volume growth) could constrain margin expansion.

Upcoming Catalysts

  • No upcoming PDUFA dates, AdComms, or pivotal readouts for Cablivi in the next 12 months. The pediatric label expansion (December 2025/January 2026) was the most recent regulatory catalyst.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 10

Hover a chip for the title
1 fda.gov2 fda.gov3 prnewswire.com4 sanofi.com5 sec.gov6 accessdata.fda.gov7 medaptly.com8 sanofi.com9 reuters.com10 stockanalysis.com